<DOC>
	<DOCNO>NCT00565318</DOCNO>
	<brief_summary>The purpose study investigate effect benfotiamine supplementation patient diabetic nephropathy , determine whether slow progression end-stage renal disease ( ESRD ) .</brief_summary>
	<brief_title>Benfotiamine Diabetic Nephropathy</brief_title>
	<detailed_description>There worldwide increase prevalence type 2 diabetes mellitus , parallel increase number patient reach dialysis diabetic nephropathy . Much fivefold increase patient receive dialysis treatment occur past two decade attributable type 2 diabetes diabetic nephropathy . Diabetes lead cause end-stage renal disease ( ESRD ) , 40 % new case ESRD occur patient diabetes . Benfotiamine show reduce diabetic nephropathy retinopathy animal experimental model . We hypothesize benfothiamine supplementation patient diabetic nephropathy ameliorate effect albuminuria/proteinuria hyperglycaemia oxidative stress advance glycation end-products ( AGEs ) accumulation renal tissue , thereby decrease inflammatory response fibrotic response , cause slow progression ESRD consequence . Intervention : The intervention duration 12 week group . - Group A : Benfotiamine ( 300 mg ) 3x 1 film coat tablet daily ( 900 mg daily dose benfotiamine ) - Group B : Placebo 3x 1 film coat tablet daily</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Benphothiamine</mesh_term>
	<criteria>Type 2 diabetes mellitus Patients treatment angiotensin convert enzyme inhibitor ( ACEi ) and/or angiotensin II antagonist ( AIIA ) unchanged dose least 3 month Active diabetic nephropathy indicate presence microalbuminuria ( 15300 mg/24 h urine ) least two sample within 26 week advance inclusion trial HbA1c &lt; 8.5 % , high HbA1c &lt; 9.5 % acceptable treat physician patient accept strive low value unreachable goal ( patient high HbA1c value one one would expect benefit treatment benfotiamine ) eGFR ( estimate MDRD formula ) &gt; 30 ml/min Males postmenopausal female Written inform consent Renal impairment cause diabetes Stage disease severe indicate Inclusion criterion ( macroalbuminuria renal insufficiency ) Severe hypoglycemia last 3 month , need help another person Severe hepatopathy ( laboratory value three time higher normal Endocrine disorder , e.g . hyper/hypothyroidism Blood pressure &gt; 160/90 mmHg Severe cardiac function disturbance severe heart rhythm disturbances Neoplasm 's ( exclude history treat skin cancer type basal cell carcinoma BCC squamous cell carcinoma SCC ) Severe general disease mental disorder make participation study impossible Drug abuse Female patient pregnancy lactation period female patient active menses past year Hypersensitivity benfotiamine HbA1c &gt; 9.5 % Use thiamine contain supplement last 3 month Participation another study within one month join benfotiamine study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Benfotiamine</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Nephropathy</keyword>
</DOC>